MEETING AGENDA

November 14th 2026

Virtual Meeting

Register & Meet Online

Hope
Hematology & Oncology Practice Exchange
SUMMIT III

AMGEN

ACCREDITED CME

Hema/Onco Welcoming Session

TIME	TOPIC	SPEAKER
09:50 – 10:00	Opening	Dr. Hesham Sabry Dr. Mohamed Elawadi

Oncology

TIME	TOPIC	SPEAKER	MODERATOR
10:00 – 11:10	Session 1: ASCO & ESMO 2026 Updates in Thoracic and Gastrointestinal Oncology		
10:00 – 10:20	ASCO & ESMO 2026 Highlights in Thoracic Oncology	Dr. Ahmed Al Lehebi	Dr. Fahad Ibn Shamsah
10:20 – 10:40	ASCO & ESMO 2026 Highlights in GI Oncology	Dr. Ali Al Qahtani	
10:40 – 11:00	ASCO & ESMO 2026 Highlights in mCRC: Precision Oncology and Emerging Treatment Paradigms	Dr. Abdullah Al Sharm	
11:00 – 11:10	Panel Discussion		
11:10 - 13:45	Session 2: Optimizing the Treatment Journey in Small Cell Lung Cancer		
11:10 – 11:30	SCLC landscape: Epidemiology, Disease Burden, Relapse Patterns, Unmet Needs, and Emerging First-Line Maintenance Evidence (DeLLphi-305; Investigational)	Dr. Abdulrahman Al Ghabban	Prof. Khalid Al Saleh
11:30 – 11:50	DLL3 Biology and Rationale for Targeted Immunotherapy	Dr. Samah Al Rehaily	
11:50 – 12:10	DeLLphi-304: Phase 3 Evaluation of Tarlatamab in Second-Line SCLC (Investigational)	Dr. Pedro Rocha	Dr. Turki Al Fayea
12:10 – 12:30	Patient Selection, Step-Up Dosing, Administration, and Monitoring in Relapsed SCLC	Dr. Ahmed Al Anazi	
12:30 - 12:50	Panel Discussion		
12:50 - 13:00	Prayer and Break		
13:00 - 13:20	Managing CRS and ICANS: Clinical Insights and Best Practices	Dr. Waleed Al Selwi	Dr. Ali Alfakeeh
13:20 - 13:35	DeLLphi-308: Phase 1b Evaluation of Subcutaneous Tarlatamab in ES-SCLC (Investigational)	Dr. Ahmed Refae	
13:35 - 13:45	Panel Discussion		
13:45 - 14:55	Session 3: Precision Oncology and Treatment Optimization in mCRC		
13:45 - 14:05	Optimizing Anti-EGFR Therapy in First Line and Maintenance	Dr. Kanan Al Shammari	Dr. Nedal Bukhari
14:05 - 14:25	Dual Pathway Inhibition in KRAS G12C mCRC: Sotorasib Plus Panitumumab	Dr. Mohammad Al Garni	
14:25 - 14:45	Anti-EGFR Re-Challenge in mCRC: Patient Selection and Clinical Evidence	Dr. Shouki Bazarbashi	
14:45 - 14:55	Panel Discussion		
14:55 - 16:40	Session 4: Expert Case Discussions and Real-World Practice in SCLC & mCRC		
14:55 - 15:10	Tarlatamab Patient Selection and Sequencing in Relapsed SCLC – Case 1	Dr. Abdullah Al Twairgi	Dr. Bandar Al Mutairi
15:10 - 15:25	Case 2: Durable Complete Response with Tarlatamab in ES-SCLC	Dr. Abdulrahman Al Shehri	
15:25 - 15:35	Break		
15:35 - 15:50	Real-World Clinical Experience with Sotorasib in KRAS G12C-Mutated mCRC	Dr. Hamed Al Husaini	Dr. Fahad Al Mugbel
15:50 - 16:05	KRAS G12C-Mutated mCRC: Treatment with Sotorasib Plus Panitumumab	Dr. Tarek Salah	
16:05 - 16:20	Real-World Panitumumab Experience in mCRC: Treatment and Maintenance	Dr. Abdulraheem Al Shangiti	
16:20 - 16:40	Panel Discussion		
16:40 - 17:00	Closing Remarks and Meeting Close		

Hematology

TIME	TOPIC	SPEAKER	MODERATOR
10:00 - 11:15	Session 1: Optimizing Ph-ve ALL Treatment (Adult/Pedia)		
10:00 - 10:20	Adult Ph-Negative ALL: Deeper Remissions and Improved Treatment in Front Line	Dr. Mansour Al Fayez	Dr. Ahmed Al Harbi
10:20 – 10:40	Saudi Pediatric ALL Consensus 2026	Dr. Wasil Jastaniah	
10:40 – 11:00	How I Treat Adult Ph-Negative (NGH Followed Protocol)	Dr. Hind Salamah	
11:00 – 11:15	Panel Discussion		
11:15 - 12:30	Session 2: Optimizing Ph+ve ALL Treatment (Adult/Pedia)		
11:15 - 11:35	Adult Ph-Positive ALL: Chemo-Free Approaches in Front Line - Combination Therapy	Dr. Mohammad Al Wadi	Dr. Salman Al Harbi
11:35 - 11:55	Managing Immunotherapy Toxicities in Clinical Practice	Dr. Wael Al Anazi	
11:55 - 12:15	How I Treat Pediatric Ph-Positive ALL (NGH Followed Protocol)	Dr. Basheer Ahmed	
12:15 - 12:30	Panel Discussion		
12:30 - 12:45	Prayer & Break		
12:45 - 13:45	Session 3: Optimizing ALL Patients Treatment Journey (Adult/Pedia)		
12:45 - 13:10	Updates in Management of Ph - ALL	Dr. Saleem Eldadah	Dr. Amal Al Beihany
13:10 - 13:30	Management Strategies for Ph - B-Cell ALL in Pediatric: the KASCH-NGHA Experience	Dr. Mohammed Al Taweel	
13:30 - 13:45	Panel Discussion		
13:45 - 14:00	Break		
14:00 - 15:00	Session 4 : Multiple Myeloma / ITP		
14:00 - 14:25	Quadruplet Therapy in Newly Diagnosed Multiple Myeloma: Are We Ready for a New Standard?	Dr. Ghazi Al Otaibi	Dr. Sultan Al Otaibi
14:25 - 14:45	Long-Term Outcomes and Treatment-Free Remission in ITP	Dr. Ruah Alyamany	
14:45 - 15:00	Panel Discussion		
15:00	Closing Remarks		

Virtual Meeting and Privacy Notice

This is a personal invitation for the invited healthcare professional only. Please do not extend it to spouses or guests.
Screenshots or photographs may be taken during the virtual meeting. Any use or distribution will follow applicable consent and privacy requirements.

In accordance with applicable Saudi laws, transfers of value to healthcare professionals will be reported to the Saudi Food and Drug Authority (SFDA).
The report may include personal information such as your first and last name, specialty, professional classification number, national ID, email address, and mobile number.
For this purpose, your personal information may be disclosed to Amgen affiliates and trusted third parties supporting delivery of our services,
ncluding those located outside Saudi Arabia.

For questions about your personal data, please contact Amgen's Data Protection Officer at privacyoffice@amgen.com.
Please scan the QR code below to review the Data Privacy Statement.